Dynacure Wins Ernst & Young’s Prix “Born Global” Award siteadmin2020-11-07T02:28:09-08:00September 18, 2019|
Dynacure to Present at Chardan’s 3rd Annual Genetic Medicines Conference siteadmin2020-11-07T02:29:21-08:00September 11, 2019|
Dynacure Appoints David Garrett as Chief Financial Officer siteadmin2020-11-07T02:30:36-08:00September 3, 2019|
Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’ siteadmin2020-11-07T02:31:59-08:00August 8, 2019|
Dynacure Receives Orphan Drug Designation in the EU for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’ siteadmin2020-11-07T02:33:31-08:00July 11, 2019|
Dynacure Announces Approval of Clinical Trial Application for DYN101, an Antisense Medicine to Treat Rare Disease ‘Centronuclear Myopathies’ siteadmin2020-11-07T02:35:45-08:00April 30, 2019|
Dynacure receives Research Grant from the Programme d’Investissements d’Avenir (PIA3) Grand Est operated by Bpifrance to Expand Development of Lead Antisense Program Dyn101 for Rare Disease ‘Centro Nuclear Myopathies’ (CNM) siteadmin2020-11-07T02:37:31-08:00April 25, 2019|
Dynacure promotes Belinda Cowling (PhD) to Chief Scientific Officer and Leen Thielemans (PhD) to Chief Development Officer siteadmin2020-11-07T02:38:39-08:00February 12, 2019|
Dynacure appoints Georges Gemayel (PhD) as Chairman to its Board of Directors siteadmin2020-11-07T02:39:50-08:00October 9, 2018|
Innovative modelling approach by Dynacure/ISMS results in the 1st peer reviewed study on quantification of the centronuclear myopathy patient population siteadmin2020-11-07T02:44:42-08:00August 31, 2018|
